EPCAM and cancer: To further test effects of EGF on EpCAM expression/RIP in a broader panel of cell lines, cell surface expression of EpCAM was assessed in HNSCCs (FaDu, Kyse30, Cal27, Cal33) and in colon (HCT8), breast (MCF7, MDA-MB-231), endometrial (RL95-2), and prostate (Du145) cancer cells following EGF treatment.